MERK Merck Tbk

12 May 2022 12:21 (11 hari lalu) - By Ludwig Burger (Reuters) - Germany's Merck KGaA said it expects earnings growth of up to 9% this year, mainly driven by drugmakers' demand for its laboratory gear business, but flagged risks related to lockdown measures in China. In a statement on Thursday, the diversified group predicted growth of 5% to 9%, excluding the effect of currency swings and any acquisitions, for adjusted earnings before interest, tax, depreciation and amortisation (EBITDA), with the Life Science division as a key growth driver. It said the forecast was based on expectations that energy and raw material prices remain high and that the COVID-19 lockdown in China ...

29 Apr 2022 17:58 (24 hari lalu) - By Colin Kellaher Merck & Co. on Friday said the European Commission approved the expanded use of its blockbuster cancer drug Keytruda in certain patients with cervical cancer. The Kenilworth, N.J., drug maker said the approval covers Keytruda in combination with chemotherapy, with or without bevacizumab, for the treatment of persistent, recurrent or metastatic cervical cancer in adults whose tumors express PD-L1, combined positive score >=1. Merck said the approval marks the first immunotherapy-based regimen cleared in Europe for that patient population. Keytruda, a cancer drug that harnesses a patient's immune system to fight tumors, is ...

29 Apr 2022 03:26 (24 hari lalu) - The most-watched biotechnology exchange-traded fund is down some 32% this year. But the evaporation of investor confidence in the sector hasn’t made potential acquisitions any cheaper for big pharma buyers yet, according to Merck ’s chief financial officer. “We’ve yet to see the seller change their mind-set on what the value of their company is,” says CFO Caroline Litchfield, speaking to Barron’s on Thursday. Earlier in the day, Merck (ticker: MRK) reported first-quarter earnings that beat Wall Street expectations, and were 84% higher than the same quarter in 2021. Shares of Merck rose 5.3% at in the early afternoon. “I think the world live ...

29 Apr 2022 02:49 (24 hari lalu) - Investors have found safety in the big pharmaceutical stocks this year. Some of those names have popped, but they are still arguably cheap. Merck & Co. (MRK), AbbVie (ABBV), Regeneron Pharmaceuticals (REGN), and Vertex Pharmaceuticals (VRTX) have seen their stocks gain 16%, 15%, 7%, and 21% for the year to date, respectively. That crushes the S&P 500 ’s 12% loss. While most stocks suffer from slowing economic growth —the Federal Reserve is raising interest rates to fight inflation, which has only worsened because of the Russia-Ukraine war—Big Pharma offers safety. Those companies’ earnings don’t depend on the strength of the economy. Drug d ...

28 Apr 2022 22:54 (24 hari lalu) - The Dow Jones Industrial Average is up Thursday morning with shares of Merck and Visa seeing positive momentum for the index. Shares of Merck MRK, +4.09% and Visa V, +2.58% are contributing to the blue-chip gauge's intraday rally, as the Dow DJIA, +0.37% was most recently trading 140 points, or 0.4%, higher. Merck's shares have gained $3.59 (4.3%) while those of Visa have gained $6.11, or 2.9%, combining for a roughly 64-point bump for the Dow. Salesforce Inc. CRM, +2.88%, Apple Inc. AAPL, +2.70%, and Nike NKE, +2.35% are also contributing significantly to the gain. A $1 move in any one of the 30 components of the index equates to a ...

Artikel lain:

28 Apr 2022 23:53 (24 hari lalu) - Shares of Merck and Salesforce Inc. are seeing strong returns Thursday afternoon, leading the Dow Jones Industrial Average rally. Shares of Merck MRK, +4.86% and Salesforce Inc. CRM, +5.23% are contributing around a quarter of the index's intraday rally, as the Dow DJIA, +1.58% was most recently trading 492 points higher (1.5%). Merck's shares have risen $4.15, or 4.9%, while those of Salesforce Inc. are up $8.19 (4.7%), combining for an approximately 81-point boost for the Dow. Apple Inc. AAPL, +4.20%, Nike NKE, +4.14%, and Home Depot HD, +3.74% are also contributing significantly to the gain. A $1 move in any of the index's 30 components ...

28 Apr 2022 20:46 (25 hari lalu) - Behind strong returns for shares of Visa and Merck, the Dow Jones Industrial Average is climbing Thursday morning. The Dow DJIA, +0.46% is trading 145 points, or 0.4%, higher, as shares of Visa V, +3.08% and Merck MRK, +3.66% have contributed to the blue-chip gauge's intraday rally. Visa's shares have climbed $7.32, or 3.4%, while those of Merck have risen $2.84, or 3.4%, combining for an approximately 67-point bump for the Dow. Other components contributing significantly to the gain include Salesforce Inc. CRM, +3.80%, Nike NKE, +3.06%, and Apple Inc. AAPL, +1.99%. A $1 move in any of the Dow's 30 components results in a 6.59-point swing. E ...

28 Apr 2022 19:28 (25 hari lalu) - By Geoffrey Smith Investing.com -- Stocks in focus in premarket on Thursday, 28th April. Please refresh for updates. - Meta Platforms (NASDAQ: FB) rose 14.3% after the owner of Facebook indicator reported a surprisingly large gain in users in the quarter, suggesting that Instagram Reels is holding its own in competition with TikTok. Slowing revenue growth and a big loss on developing ‘Metaverse’ themed products were, apparently, fully priced in. - Qualcomm (NASDAQ: QCOM) stock rose 6.2% after the chipmaker beat forecasts with its quarterly numbers and raised its guidance. Sales were particularly strong in the mobile phone segment. Overnight ...

28 Apr 2022 19:17 (25 hari lalu) - Merck on Thursday reported financial results for the first quarter of the fiscal year that beat Wall Street expectations, sending shares up 2.1% in premarket trading. The company reported sales for the quarter of $15.9 billion, up 50% compared to the same period last year and better than the FactSet consensus estimate of $14.6 billion. Non-GAAP earnings for the quarter were $2.13 per share, up from 84% compared to the same period last year and better than the FactSet consensus estimate of $1.83 per share. The stronger-than-expected earnings reflect both the blockbuster sales of Merck’s (ticker: MRK) new Covid-19 antiviral pill, but also a ...